var data={"title":"Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390290?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information\" class=\"drug drug_general\">see &quot;Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information&quot;</a> and <a href=\"topic.htm?path=naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-patient-drug-information\" class=\"drug drug_patient\">see &quot;Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348239\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Clear Eyes Redness Relief [OTC];</li>\n      <li>GoodSense Redness Relief Plus [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348240\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Albalon;</li>\n      <li>Clear Eyes;</li>\n      <li>Diopticon;</li>\n      <li>Naphcon Forte;</li>\n      <li>Odan-Naphazoline;</li>\n      <li>Redness Eye Drops;</li>\n      <li>Refresh Redness Relief;</li>\n      <li>Soothe Redness</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512704\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent, Ophthalmic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Vasoconstrictor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512730\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information\" class=\"drug drug_general\">see &quot;Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Ocular redness, irritation:</b> Limited data available: Children &ge;6 years and Adolescents: Ophthalmic solution 0.012% to 0.03% (OTC products): Instill 1 to 2 drops in affected eye up to four times daily (Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Decrease in eye redness (vasoconstrictor):</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prescription: 0.1% solution: 1 to 2 drops into conjunctival sac every 3 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OTC: 0.012% or 0.03% solution: 1 to 2 drops into affected eye(s) up to 4 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348361\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clear Eyes Redness Relief: Naphazoline 0.0125% and glycerin 0.2% (6 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Redness Relief Plus: Naphazoline 0.03% and glycerin 0.5% (15 mL) [contains benzalkonium chloride, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348242\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512731\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical ocular: Instill drop(s) into conjunctival sac of affected eye(s); finger pressure should be applied to lacrimal sac during and for 1 to 2 minutes after instillation to decrease risk of absorption and systemic reactions; avoid contact of bottle tip with skin or eye</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348296\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512724\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Topical ocular vasoconstrictor (FDA approved in adults); relief of redness of the eye due to minor irritation; temporary relief of burning and irritation due to dry eyes; as a protectant against further irritation or dryness of the eye (OTC: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15801079\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348284\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Ophthalmic: Blurred vision, eye discomfort, eye irritation, eye redness, increased intraocular pressure, lacrimation, mydriasis, punctuate keratitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348247\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to naphazoline or any component of the formulation; narrow-angle glaucoma or anatomically narrow angle</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for ophthalmic vasoconstrictors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity can not be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348250\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular abnormalities or hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection/injury: Use with caution in patients with local infection or injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzalkonium chloride: May contain benzalkonium chloride which may be absorbed by soft contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For topical ophthalmic use only. Do not touch tip of container to any surface, the eyelids, or the surrounding area. Discontinue use and notify health care provider if symptoms worsen or persist &gt;48 hours (&gt;72 hours [OTC]) or if symptoms of systemic absorption occur (ie, dizziness, headache, nausea, decrease in body temperature, drowsiness). Overuse may produce increased redness of the eye; pupils may become enlarged temporarily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC use): Discontinue use and contact health care provider if eye pain or changes in vision occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Accidental ingestion: Accidental ingestion by children of nonprescription (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299742\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348288\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16027&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348244\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348245\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50637027\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Increased redness and irritation, discomfort, blurring, increased ocular pressure, or tear production</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Systemic: Signs/symptoms of overexposure (dizziness, headache, nausea, sweating, nervousness, drowsiness, weakness, hypertension, cardiac irregularities, and hyperglycemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9348297\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322359\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clear Eyes Redness Relief Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.012-0.2% (6 mL): $1.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390234\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Albalon (AE, BH, CH, CY, EG, HK, IQ, IR, JO, LY, NL, OM, QA, SA, SY, TH, YE);</li>\n      <li>Albalon Liquifilm (AU);</li>\n      <li>Albasol (CO);</li>\n      <li>Alivioftal (CO);</li>\n      <li>Apizolin (JO, KW);</li>\n      <li>Claroft (BR);</li>\n      <li>Clearine (IN);</li>\n      <li>Iridina Due (HU);</li>\n      <li>Miraclar (ES);</li>\n      <li>Murine Clear Eyes (AR, AU);</li>\n      <li>Murine Irritation &amp; Redness Relief (MT);</li>\n      <li>Murine Irritation and Redness Relief (IE);</li>\n      <li>Naftazolina (IT);</li>\n      <li>Naphcon (AE, BE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Naphcon Forte (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Naphcon-F (CO);</li>\n      <li>Naphtears (CL, PE, PK, PY);</li>\n      <li>Optrex (AR);</li>\n      <li>Proculin (RO);</li>\n      <li>Red Off (UY);</li>\n      <li>Riazolin (AE, KW, QA);</li>\n      <li>Sanorin (CZ, EE);</li>\n      <li>Tele-Stulin (DE);</li>\n      <li>Vasoclear-V (PH);</li>\n      <li>Vericlar (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vizol (HR);</li>\n      <li>Zolina (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alvarez-Pitti J, Rodr&iacute;guez-Varela A, Morales-Carpi C, Lurbe E, Esta&ntilde; L. Naphazoline intoxication in children. <i>Eur J Pediatr</i>. 2006;165(11):815-816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-pediatric-drug-information/abstract-text/16788830/pubmed\" target=\"_blank\" id=\"16788830\">16788830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clear Eyes Cooling Redness Relief (naphazoline) [prescribing information]. Irvington, NY: Prestige Brands Holdings Inc; January 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clear Eyes Maximum Redness Relief (naphazoline) [prescribing information]. Irvington, NY: Prestige Brands Holdings Inc; February 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clear Eyes Redness Relief (naphazoline) [prescribing information]. Irvington, NY: Prestige Brands Holdings Inc; July 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Euwema MS, Swanson TJ. Toxicity, deadly single dose agents. <i>StatPearls Publishing</i>. 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-pediatric-drug-information/abstract-text/28722879/pubmed\" target=\"_blank\" id=\"28722879\">28722879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U.S. Food and Drug Administration. October 25, 2012. Available at <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm</a>. Accessed September 5, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naphazoline (naphazoline hydrochloride solution/drops) [prescribing information]. Lake Forest, IL: Akorn, Inc; March 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naphcon A (naphazoline and pheniramine) [prescribing information]. Forth Worth, TX: Alcon Laboratoriesl, Inc.; November 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wenzel S, Sagowski C, Laux G, Kehrl W, Metternich FU. Course and therapy of intoxication with imidazoline derivate naphazoline. <i>Int J Pediatr Otorhinolaryngol</i>. 2004;68(7):979-983.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-pediatric-drug-information/abstract-text/15183593/pubmed\" target=\"_blank\" id=\"15183593\">15183593</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16027 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9348239\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9348240\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10512704\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10512730\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9348361\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9348242\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10512731\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9348296\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10512724\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15801079\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9348284\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9348247\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9348250\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299742\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9348288\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9348244\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9348245\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50637027\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9348297\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322359\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390234\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16027|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information\" class=\"drug drug_general\">Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information</a></li><li><a href=\"topic.htm?path=naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-patient-drug-information\" class=\"drug drug_patient\">Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Patient drug information \t</a></li></ul></div></div>","javascript":null}